BioSpace News Archive

Armata Pharmaceuticals, Inc., a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, announced that it has entered into a securities purchase agreement to sell Armata common stock and warrants to Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc., Armata’s largest shareholder.

The global market for smart e-pants has been expanding due to the need to improve health of disabled and bedridden persons.

The global microbiome therapeutics market is anticipated to rise progressively owing to the growing need for precise, reliable, and fast treatment for diseases like phenylketonuria, hepatic encephalopathy, C. difficile infection, and multidrug resistant urinary tract infection.

Medical and industrial gloves, primarily used in the medical sector and non-medical areas such as the food processing industry, commercial manufacturing, and cleaning applications are seeing increasing demand.

Fact.MR – A Market Research and Competitive Intelligence Provider: By the end of 2022, the global orthopedic implants market is estimated to be worth US$ 468 million, growing at a CAGR of 6.7% over the forecast period of 2022-2032.

Perfuze, a medical device company developing next-generation catheter-based aspiration technology to treat large vessel occlusion acute ischemic stroke, has closed a €22.5 million Series A investment round.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the appointment of Dr. Rainer Metzger to its Strategic Advisory Board.

Active Biotech announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-tumor activity of the Company’s siRNA drug candidate, STP707 with intravenous administration in the United States.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that company management is scheduled to webcast a presentation from the 11th Annual SVB Leerink Global Healthcare Conference.